Novo Nordisk (NOVOB DC) exec says early oral obesity trends look incremental rather than cannibalistic and roughly 80% of Wegovy pill users are GLP-1 naive
- Launch is bringing in new prescribers and new patients, and switching from competitive products appears to be more meaningful than switching from injectable Wegovy.
Context
This update from Novo Nordisk on their oral obesity treatment suggests that the market is expanding rather than just shifting existing Wegovy users. Approximately 80% of new users are GLP-1 naive, indicating a significant influx of new patients rather than a simple swap, which could bode well for overall sales growth. Investors may see this as a positive signal for the continuing success of Novo Nordisk's product portfolio, potentially affecting their stock performance and that of competitors in the obesity treatment space.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#EUROPEAN EQUITIES